Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

STRO 001

Drug Profile

STRO 001

Alternative Names: STRO-001

Latest Information Update: 17 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sutro Biopharma
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Maytansinoids
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Lymphoma; Multiple myeloma

Most Recent Events

  • 16 Jul 2019 Updated adverse events data from a phase I trial in Multiple myeloma and lymphoma (Late-stage disease, Second-line therapy or greater) released by Sutro Biopharma
  • 16 May 2019 Adverse events, efficacy and pharmacokinetics data from a phase I trial in Multiple myeloma and lymphoma presented at the 24th European Hematology Association (EHA-2019)
  • 12 Oct 2018 STRO 001 receives Orphan Drug status for Multiple myeloma in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top